Companion Diagnostics

The only way to know exactly what drug to use for the exact genetic mutation that’s causing your cancer

Download Companion Diagnostics PDF

Prescribe targeted oncology therapeutics considering panels of resistance genetic variants

Drugs are designed to bind to specific protein targets. Common genetic variation affects the drug binding site and action of the protein and can affect the efficacy of a drug, but this is generally not considered in the preclinical testing prior to a clinical trial. For the most popular precision oncology therapeutics, some resistance mutations are later identified and considered when prescribing a companion diagnostic test. However, there is no systematic approach to identify drug resistance. If this information were available to oncologists, it could be used to select among different drugs for more effective data-driven treatment.

Five Facts

  • Genetic variation can produce drug resistance
  • Little is known about drug resistance for precision oncology
  • GMLs with and without drugs can identify all resistance mutations in a target for a drug
  • Creates genetic profiles your team can compare fast
  • Making drugs more effective

Powering precision prescriptions because patients and payers want drugs that work

Attempt to match a drug to a patient with a single genetic mutation

Heligenics matches many more patients using all mutations

We create genetic profiles for drugs that your team can compare quickly

Mapping out up to 95% of gene resistance mutations and their causative effects can now be done in months instead of years.

Download a Companion Diagnostics PDF

Kindly fill out the form below to download a handy PDF.

    Heligenics Logo